SGLT2 inhibitors reduce the risk of developing type 2 diabetes by approximately 19-21% in people with prediabetes who also have heart failure or chronic kidney disease, according to a 2026 narrative review analyzing current research. These medicines also help with weight loss, improve insulin sensitivity, and lower blood pressure. However, major medical guidelines don’t yet recommend them for preventing diabetes in people with prediabetes alone, and more research is needed before they become standard prevention therapy
A new review of research shows that SGLT2 inhibitors, a class of medicines already used for diabetes and heart disease, might help prevent type 2 diabetes in people with prediabetes, especially those with heart or kidney problems. According to Gram Research analysis, these drugs reduced the risk of developing diabetes by about 19-21% in high-risk patients. The medicines also help people lose weight, improve how their body uses insulin, and lower blood pressure. However, doctors aren’t recommending them yet for everyone with prediabetes because we need more research to be sure they work for all patients.
Key Statistics
A 2026 narrative review found that SGLT2 inhibitors reduced the incidence of new-onset type 2 diabetes by approximately 19-21% in adults with prediabetes who also had heart failure or chronic kidney disease, based on two contemporary meta-analyses.
According to research reviewed by Gram, SGLT2 inhibitors promote modest weight reduction, improve insulin sensitivity, lower blood pressure, and reduce hepatic lipid accumulation in people with prediabetes, though these medicines are not yet recommended by current guidelines for prediabetes prevention alone.
A 2026 review of SGLT2 inhibitors noted that while these drugs are generally well tolerated, they carry an increased risk of genitourinary infections and a rare but serious risk of euglycemic diabetic ketoacidosis that patients should discuss with their doctors.
The Quick Take
- What they studied: Whether SGLT2 inhibitors (a type of diabetes medicine) can help prevent type 2 diabetes in people with prediabetes
- Who participated: This was a review of many different studies published up to February 2026. The review looked at research involving adults with prediabetes, with special focus on those who also had heart failure or chronic kidney disease
- Key finding: SGLT2 inhibitors reduced the chance of developing type 2 diabetes by roughly 19-21% in people with prediabetes who also had heart or kidney disease, based on two major analyses of multiple studies
- What it means for you: If you have prediabetes and heart or kidney problems, SGLT2 inhibitors might be worth discussing with your doctor. However, these medicines aren’t yet recommended as a standard prevention tool for people with prediabetes alone. Lifestyle changes like diet and exercise remain the most important first step
The Research Details
This was a narrative review, which means researchers searched through published studies and summarized what they found about SGLT2 inhibitors and prediabetes. They looked at original research studies, meta-analyses (which combine results from many studies), and other high-quality reviews published through February 2026 in the PubMed database.
A narrative review is different from a strict systematic review because it gives researchers more flexibility in choosing which studies to include and how to interpret them. This approach is useful for getting a broad overview of a topic, but it can be influenced by the reviewer’s choices about which studies matter most.
The researchers focused on understanding how SGLT2 inhibitors work in people with prediabetes and whether they might prevent the development of type 2 diabetes. They also looked at side effects and compared SGLT2 inhibitors to other medicines that are already used for prevention.
This review matters because prediabetes affects about 1 in 8 adults worldwide, and many of these people will eventually develop type 2 diabetes if nothing changes. Finding new medicines that could prevent this progression could help millions of people avoid serious health problems. SGLT2 inhibitors are already approved and widely used for other conditions, so if they work for prediabetes, they could be available relatively quickly. However, we need to understand both the benefits and risks before recommending them to everyone.
This is a narrative review, which means it provides a helpful overview but isn’t as rigorous as a systematic review with strict rules about which studies to include. The review included studies up to February 2026 and considered multiple types of evidence. The main limitation is that the reviewers had some flexibility in choosing which studies to emphasize. The review itself notes that dedicated randomized controlled trials (the gold standard for testing medicines) are still needed specifically in prediabetes patients before these drugs can be widely recommended for prevention
What the Results Show
Research shows that SGLT2 inhibitors have several positive effects in people with prediabetes. Most importantly, two major analyses combining results from multiple studies found that these medicines reduced the risk of developing type 2 diabetes by approximately 19-21% in people who had prediabetes along with either heart failure or chronic kidney disease.
Beyond preventing diabetes, SGLT2 inhibitors produced other health benefits. Studies showed these medicines helped people lose weight (though the weight loss was modest), improved how well their bodies use insulin, lowered blood pressure, and reduced the amount of fat stored in the liver. These are all important because they address multiple risk factors for heart disease and diabetes.
The medicines were generally well tolerated, meaning most people didn’t experience serious side effects. This is important because it suggests SGLT2 inhibitors could be a practical option if they’re recommended for prevention.
Beyond the main diabetes prevention findings, the review highlighted several other important outcomes. SGLT2 inhibitors improved insulin sensitivity, which means the body’s cells became better at responding to insulin and taking up glucose from the blood. This is a key marker of metabolic health. The medicines also had favorable effects on liver fat metabolism, which is important because fatty liver disease often accompanies prediabetes and increases heart disease risk. Blood pressure reduction was another consistent benefit, which matters because high blood pressure is a major risk factor for heart attacks and strokes in people with prediabetes.
SGLT2 inhibitors join several other medicines that have already been shown to help prevent type 2 diabetes in people with prediabetes. Metformin, pioglitazone, acarbose, and GLP-1 receptor agonists (another class of diabetes drugs) all have evidence supporting their use for prevention. What makes SGLT2 inhibitors potentially different is that they appear to have additional benefits for heart and kidney health, which is why they show particular promise in people who have both prediabetes and these other conditions. However, unlike metformin, which is already widely recommended for prediabetes prevention, SGLT2 inhibitors are not yet endorsed by major guidelines for this purpose alone.
The review identifies several important limitations. First, while SGLT2 inhibitors show promise in people with prediabetes who also have heart failure or kidney disease, there haven’t been large clinical trials specifically designed to test whether these medicines prevent diabetes in people with prediabetes alone. This is a significant gap because the benefits might be different in this broader population. Second, the cost of SGLT2 inhibitors is higher than some alternatives like metformin, which could limit access for many patients. Third, it’s unclear how long people would need to take these medicines to prevent diabetes, would it be for years or indefinitely? This uncertainty makes it hard to recommend them routinely. Finally, while side effects are usually mild, SGLT2 inhibitors do increase the risk of urinary tract and genital infections, and there’s a rare but serious risk of a condition called euglycemic diabetic ketoacidosis
The Bottom Line
Current medical guidelines (as of 2026) do not yet recommend SGLT2 inhibitors specifically to prevent type 2 diabetes in people with prediabetes alone. However, if you have prediabetes AND heart failure or chronic kidney disease, discussing SGLT2 inhibitors with your doctor is reasonable, as they may provide benefits for both conditions. For people with prediabetes without these other conditions, lifestyle changes, eating a healthier diet, increasing physical activity, and losing weight, remain the most important and well-proven prevention strategy. Metformin is another option that’s already recommended by guidelines for prediabetes prevention. The evidence for SGLT2 inhibitors in pure prediabetes is still considered preliminary (moderate confidence level) and requires more research before routine use can be recommended
People with prediabetes who also have heart failure or chronic kidney disease should definitely discuss SGLT2 inhibitors with their doctor, as the evidence is strongest in this group. People with prediabetes alone should focus on lifestyle changes first and talk to their doctor about whether metformin might be appropriate. People already taking SGLT2 inhibitors for diabetes, heart disease, or kidney disease don’t need to change anything based on this review. People without prediabetes don’t need to consider these medicines for diabetes prevention
If you start taking SGLT2 inhibitors, you might notice some benefits relatively quickly, blood pressure can improve within weeks, and weight loss often begins within a few weeks to months. However, the main benefit (preventing type 2 diabetes) would take much longer to evaluate. Most studies looked at outcomes over 1-3 years. It’s important to understand that these medicines work best when combined with lifestyle changes, not as a replacement for them. You shouldn’t expect to see major results without also improving your diet and exercise habits
Frequently Asked Questions
Can SGLT2 inhibitors prevent type 2 diabetes in people with prediabetes?
SGLT2 inhibitors reduce diabetes risk by about 19-21% in people with prediabetes who also have heart failure or kidney disease, based on 2026 research. However, they’re not yet recommended for prediabetes prevention alone. Lifestyle changes remain the most important first step
What are the side effects of SGLT2 inhibitors?
SGLT2 inhibitors are generally well tolerated. The most common side effects are urinary tract and genital infections. Rarely, they can cause a serious condition called euglycemic diabetic ketoacidosis. Discuss these risks with your doctor before starting treatment
Are SGLT2 inhibitors better than metformin for preventing diabetes?
Both medicines can help prevent type 2 diabetes, but metformin is already recommended by guidelines for prediabetes prevention, while SGLT2 inhibitors are not yet. SGLT2 inhibitors may offer additional heart and kidney benefits, making them particularly useful if you have those conditions alongside prediabetes
How long would I need to take SGLT2 inhibitors to prevent diabetes?
Current research doesn’t clearly answer this question. Studies typically followed patients for 1-3 years, but it’s unclear whether you’d need to take these medicines long-term or indefinitely. This uncertainty is one reason guidelines haven’t yet endorsed them for routine prediabetes prevention
Who should consider SGLT2 inhibitors for prediabetes?
People with prediabetes who also have heart failure or chronic kidney disease should discuss SGLT2 inhibitors with their doctor, as evidence is strongest in this group. People with prediabetes alone should focus on diet, exercise, and weight loss first
Want to Apply This Research?
- If your doctor prescribes an SGLT2 inhibitor, track your fasting blood glucose levels weekly and your weight monthly. Also monitor for any signs of urinary tract infections (burning during urination, urgency, frequency) and report these to your doctor immediately
- Use the app to set reminders for taking your SGLT2 inhibitor at the same time each day. Combine this with logging your meals to track diet quality and recording your exercise sessions. Set a goal to lose 5-10% of your body weight over 6 months, as this amplifies the medicine’s benefits
- Create a dashboard showing your blood glucose trends, weight progress, and blood pressure readings over time. Schedule quarterly check-ins with your doctor to review these metrics and discuss whether the medicine is working well for you. If you experience any side effects or infections, log these in the app to share with your healthcare provider
This article summarizes research about SGLT2 inhibitors and prediabetes but is not medical advice. SGLT2 inhibitors are prescription medications with potential side effects, including increased risk of urinary tract infections and a rare but serious condition called euglycemic diabetic ketoacidosis. Current medical guidelines (2026) do not recommend SGLT2 inhibitors for prediabetes prevention outside of patients who also have heart failure or chronic kidney disease. Always consult with your healthcare provider before starting, stopping, or changing any medication. This review is based on research available through February 2026 and reflects current evidence at that time. Individual results may vary, and your doctor should evaluate your specific health situation, medications, and risk factors before making treatment decisions
This research translation is published by Gram Research, the science division of Gram, an AI-powered nutrition tracking app.
